Anaergia reports Q2 results (TSX:ANRG:CA)
Anaergia press release (ANRG:CA): Q2 Revenue of C$63.9M (+97.8% Y/Y). Adjusted EBITDA improved to positive C$1.9 million, compared with an Adjusted EBITDA loss
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Anaergia press release (ANRG:CA): Q2 Revenue of C$63.9M (+97.8% Y/Y). Adjusted EBITDA improved to positive C$1.9 million, compared with an Adjusted EBITDA loss
Anaergia reports Q2 results (TSX:ANRG:CA) | Seeking Alpha
Anaergia
press release
(
ANRG:CA
): Q2
Revenue of C$63.9M (+97.8% Y/Y).
Adjusted EBITDAÂ improved to positive C$1.9 million, compared with an Adjusted EBITDAÂ loss of C$2.2 million in Q2 2025
Net loss improved to C$2.1 million, compared with a net loss of C$9.5 million in Q2 2025
More on Anaergia
Anaergia Inc. (ANRG:CA) Shareholder/Analyst Call - Slideshow
Anaergia Inc. 2026 Q1 - Results - Earnings Call Presentation
Anaergia Inc. (ANRG:CA) Q1 2026 Earnings Call Transcript
Historical earnings data for Anaergia
Financial information for Anaergia
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
P3 Health Partners forecasts $80M-$110M in 2026 adjusted EBITDA following Q2 settlements (NASDAQ:PIII)
P3 Health Partners (PIII) Q2 2026 earnings call recap: EBITDA beat, raised 2026 outlook, settlement impacts, seasonality risks & strategy.
QuidelOrtho partially recovers from earnings slide, rising 12% (QDEL:NASDAQ)
QuidelOrtho (QDEL) stock rebounds 12% after Q2 earnings beat but sharp 2026 guidance cut.
Bowman Consulting Non-GAAP EPS of $0.62 beats by $0.16, revenue of $146.12M beats by $0.32M (NASDAQ:BWMN)
Bowman Consulting press release (BWMN): Q2 Non-GAAP EPS of $0.62 beats by $0.16. Revenue of $146.12M (+19.7% Y/Y) beats by $0.32M. Full Year 2026 Guidance Bowma
Oruka Therapeutics GAAP EPS of -$0.55 misses by $0.01 (NASDAQ:ORKA)
Oruka Therapeutics press release (ORKA): Q2 GAAP EPS of -$0.55 misses by $0.01. As of June 30, 2026, Oruka had cash, cash equivalents and marketable securities